Abbott Laboratories (ABT) Total Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $35.5 billion for Q4 2021.

• In Q4 2021, Total Non-Current Liabilities fell 1.04% year-over-year to $35.5 billion; the TTM figure through Dec 2021 stood at $35.5 billion (down 1.04% YoY), while the FY2021 annual figure was $35.5 billion, down 1.04% from the prior year.
• Total Non-Current Liabilities came in at $35.5 billion for Q4 2021 at Abbott Laboratories, down from $35.9 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $40.3 billion in Q4 2017 to a low of $32.5 billion in Q4 2018.
• Average Total Non-Current Liabilities over 5 years is $35.4 billion, with a median of $35.5 billion recorded in 2021.
• Year-over-year, Total Non-Current Liabilities soared 47.07% in 2017 and dropped 19.43% in 2018.
• Over 5 years, Total Non-Current Liabilities stood at $40.3 billion in 2017, then fell by 19.43% to $32.5 billion in 2018, then increased by 0.54% to $32.6 billion in 2019, then grew by 9.86% to $35.9 billion in 2020, then dropped by 1.04% to $35.5 billion in 2021.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $35.5 billion in Q4 2021, $35.9 billion in Q4 2020, and $32.6 billion in Q4 2019.